{"organizations": [], "uuid": "0d4eb69388e6905ea34cb759b18c8201c6199d7e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://si.wsj.net/public/resources/images/BN-KN233_0928va_G_20150928151601.jpg", "site_section": "http://www.wsj.com/news/business", "section_title": "Business &amp; Finance News - Wall Street Journal", "url": "http://www.wsj.com/articles/valeants-disclosure-why-now-1445645280", "country": "US", "title": "Valeant’s Disclosure: Why Now?", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "Valeant’s Disclosure: Why Now? - WSJ", "spam_score": 0.0, "site_type": "news", "published": "2015-10-24T04:08:00.000+03:00", "replies_count": 0, "uuid": "0d4eb69388e6905ea34cb759b18c8201c6199d7e"}, "author": "Michael Rapoport", "url": "http://www.wsj.com/articles/valeants-disclosure-why-now-1445645280", "ord_in_thread": 0, "title": "Valeant’s Disclosure: Why Now?", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Of investors’ many concerns about Valeant Pharmaceuticals International Inc. and its relationship with a specialty pharmacy, one has stood out: Why is Valeant talking about this only now?\nAccounting experts say it’s a good question given that until this week, Valeant’s disclosures on the subject were slim.\nThe controversy that slammed Valeant’s shares this week centers on its ties to Philidor RX Services LLC, which helps... To Read the Full Story, Subscribe or Sign In", "external_links": [], "published": "2015-10-24T04:08:00.000+03:00", "crawled": "2015-10-24T04:09:02.866+03:00", "highlightTitle": ""}